Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Copanlisib (Primary) ; Rogaratinib (Primary)
  • Indications Carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ROCOCO
  • Sponsors Bayer

Most Recent Events

  • 18 Mar 2021 Status changed from active, no longer recruiting to completed.
  • 12 Jan 2021 Planned End Date changed from 30 Nov 2020 to 29 Jan 2021.
  • 04 Nov 2020 Planned End Date changed from 30 Sep 2020 to 30 Nov 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top